Indication
Adult Soft Tissue Sarcoma
7 clinical trials
10 products
5 drugs
Clinical trial
Phase I Randomized Study of MAGE-12 Peptide Vaccine in Patients With Refractory Metastatic Cancer Expressing MAGE-12 AntigenStatus:
Drug
interleukin-2Product
MAGE-12Product
Montanide ISA-51Clinical trial
Phase II Randomized Study of Isolated Limb Perfusion Using Melphalan With or Without Tumor Necrosis Factor in Patients With Unresectable High Grade Soft Tissue Sarcomas of the ExtremityStatus: Completed
Product
melphalanProduct
Tumor Necrosis FactorClinical trial
Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid StructuresStatus: Not yet recruiting, Estimated PCD: 2026-07-01
Product
EzabenlimabClinical trial
Real-Time Contrast Enhanced Ultrasound and Ultrasound-Based Elastography: Novel Quantitative Imaging Techniques for Early Therapy Response Assessment in SarcomasStatus: Completed, Estimated PCD: 2024-01-19
Product
DefinityClinical trial
A Multicenter, Phase Ib/II Trial of Selinexor as a Single Agent and in Combination With Imatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GISTs)Status: Active (not recruiting), Estimated PCD: 2023-04-16
Drug
SelinexorProduct
ImatinibClinical trial
A Randomized Phase II Study of Durvalumab (MEDI4736) and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue SarcomaStatus: Completed, Estimated PCD: 2022-08-12
Product
Durvalumab and TremelimumabDrug
R-CHOPClinical trial
Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine and Irinotecan (VI) for Patients With Intermediate-Risk Rhabdomyosarcoma (RMS)Status: Completed, Estimated PCD: 2014-12-31
Drug
cyclophosphamideProduct
DactinomycinProduct
IrinotecanDrug
Vincristine